Non-small Cell Lung Cancer Stage III Clinical Trial
Official title:
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer Patients Unfit for Concurrent Chemoradiotherapy: an Open Label, Two Cohorts, Prospective Trial
Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen'). However, many patients with poor performance status, older age or comorbidities may be ineligible for chemotherapy due to expected high toxicity. The present study aim to investigate the efficacy and toxicities of sequential chemo-immunotherapy plus thoracic radiotherapy for elderly and/or frail stage III NSCLC patients unfit for concurrent chemoradiotherapy, and to identify the optimal thoracic dose for this patient population.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04765709 -
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06449313 -
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06031597 -
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
|
Phase 3 | |
| Recruiting |
NCT04728724 -
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05451173 -
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT06015815 -
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
|
||
| Completed |
NCT03728556 -
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04586465 -
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT02434081 -
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
| Completed |
NCT03550482 -
Oncoxin® and Quality of Life in Cancer Patients
|
Phase 4 | |
| Recruiting |
NCT05398094 -
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
|
Phase 2 | |
| Completed |
NCT02418234 -
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
|
N/A | |
| Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05414630 -
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT04941365 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
N/A | |
| Not yet recruiting |
NCT06463665 -
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)
|
Phase 2 | |
| Active, not recruiting |
NCT04699721 -
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC
|
Phase 1 | |
| Recruiting |
NCT04878952 -
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
|
N/A |